

ANTIBODY-DRUG CONJUGATE CONTAINING HETEROCYCLIC COMPOUND
HAVING MUTANT KRAS PROTEIN DEGRADATION-INDUCING EFFECT

ABSTRACT

Provided is an antibody-drug conjugate for use in the treatment of a cancer expressing mutant KRAS, particularly, G12V mutant, G12D mutant, and G12C mutant KRAS. Also provided are a drug and a drug-linker conjugate for use in the antibody-drug conjugate. The present inventors have conjugated a heterocyclic compound having a mutant KRAS protein degradation-inducing effect, the heterocyclic compound being represented by formula (II), to an anti-EGFR antibody to prepare an antibody-drug conjugate capable of delivering the compound to an EGFR-expressing cancer. Also, a drug-linker conjugate for use in the antibody-drug conjugate or a salt thereof has been found. The antibody-drug conjugate inhibits mutant KRAS by inducing the degradation of mutant KRAS, particularly, G12V mutant, G12D mutant, and G12C mutant KRAS protein, in an EGFR-expressing cancer, and exhibits an antitumor effect.